ABOUT US
add
close
About Piramal
Leadership Team
History
Quality
Anti-capital punishment
FACILITIES
RESOURCES
add
close
Brochures
White Papers
Case Studies
Webinars
Videos
Blogs
NEWS & MEDIA
add
close
In The News
Press Releases
Awards
EVENTS
SUSTAINABILITY
PATIENT CENTRICITY
CAREERS
CONTACT US
Drug Discovery
add
close
Synthetic Chemistry
In Vitro Biology
Analytical Support Services
DMPK (In-Vitro ADME/ In-Vivo PK)
Non-GMP Kilo Lab Service
Drug Substance
add
close
API Development
Route Scouting
Process and analytical Development
Pre-GMP Scale-up
API Manufacturing
Pre-Clinical Supply
Clinical Supply
Commercial Supply
Scale-Up and Tech Transfer
Generic APIs
Product List
Special APIs Capabilities
High Potency API
Peptides
Hormonal API
Controlled Substances
Drug Product
add
close
Dosage Forms
Oral Solids
Liquids, Creams and Ointments
Sterile Injectable
Formulation Development
Pre-Formulation Studies
Analytical Development
Commercial Formulation Manufacturing
Clinical Supply
Scale Up Tech Transfer
Special Formulation Capabilities
Controlled Substances and Potent OSDs
Hormonal Formulations
Specialized Offerings
add
close
Antibody Drug Conjugates
Vaccines and Biologics
Peptides
Nutrition Solutions
add
close
Human Nutrition & Health
Vitamin Mineral Premix
Fortification Premix
Direct Vitamins
Customized Premix
Animal Nutrition & Health
Nicomix® - Vitamin Premix
Liquid Feed Supplements
Direct Vitamins
Custom Premixes & Formulations
Skincare
MaxReti® - Retinol and Diluted Forms
MaxReti® RP – Retinyl Palmitate
Food Programs
Micronutrient Premix
Therapeutic Nutrition
Staple Fortification
Vitamin A Oral Solution
Why Partner With Us?
add
close
Patient Centricity
Integrated Solution
Global Footprint
Science Collective
Customer Centricity
search
search
close
Should be more than 4 characters
search
search
close
Should be more than 4 characters
In the News
In the News
Press Releases
Awards
Featured
Piramal Pharma Limited Announces Results for Q4 and FY2024
May 11, 2024
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024
Jan 30, 2024
arrow_back_ios_new
arrow_forward_ios
Piramal Pharma Solutions Announces $80M Expansion Plan for Sterile Injectables Facility in Lexington
Sep 30, 2024
READ MORE
Piramal Pharma Solutions Commemorates Opening of Its ADC Manufacturing Expansion in Grangemouth, Scotland
Dec 18, 2023
READ MORE
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
Oct 27, 2023
READ MORE
Piramal Pharma Solutions Launches In-Vitro Biology Capabilities at Ahmedabad Discovery Services Site
Oct 17, 2023
READ MORE
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2023
Sep 30, 2023
READ MORE
Piramal Pharma Limited Announces Consolidated Results for Q1FY24
Aug 03, 2023
READ MORE
Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023
May 24, 2023
READ MORE
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
May 02, 2023
READ MORE
Piramal Pharma Solutions Supports Theracosbio With Integrated Drug Substance/drug Product Program for Bexagliflozin
Mar 29, 2023
READ MORE
Piramal Pharma Solutions Announces Production of First Batches at New Api Facility in Riverview, Michigan
Feb 15, 2023
READ MORE
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2023
Feb 08, 2023
READ MORE
Show More
